Dossier assessment
Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with relapsed and refractory multiple myeloma after at least 2 prior therapies (including lenalidomide and a proteasome inhibitor) and disease progression on the last therapy
Only positive effects (in mortality and side effects), indication of minor added benefit
Additional information
Federal Joint Committee (G-BA)
2020-04-02 A G-BA decision was published.
Project details
- Project no.
- A19-80
- Commission
- Commission awarded on 20.09.2019 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Elotuzumab - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed